Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Applied Physiology Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Department Neuroscience, School of Medicine, Isfahan University of Medical Science, Isfahan, Iran
Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Science,
Isfahan, Iran
Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Department of Biology, Faculty of Science, University of Isfahan, Isfahan, Iran
* Corresponding Address:
P.O.Box: 8174673461
Department of Immunology
Faculty of Medicine
Isfahan University of Medical
Sciences
IsfahanIran
Email: neskandari@med.mui.ac.ir
Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
SeyedjoodakiAzadeh,
AlsahebfosoulFereshteh,
EskandariNahid,
ShaygannejadVahid,
SalehiMansour,
KazemiMohammad,
ManianMostafa,
MirmosayyebOmid,
KardiMohammad Taghi.
OX40 Gene and Serum Protein Expression Profiles in Patients
with Parkinson’s Disease .
Cell J.
2018;
20(2): 177-182.
Abstract
Objective:
Inflammation of the immune system and the central nervous system has been known as an important predisposing
factor for Parkinson’s disease (PD). Increased expression of OX40 protein (CD134) is a known factor for increased inflammation
and initiation of NF-kappa-B signaling pathway in different diseases. We aimed to investigate the expression of OX40 at the
transcript and serum protein levels.
Materials and Methods:
Twenty individuals with PD and 20 healthy individuals, as controls, were enrolled in this casecontrol
study. Expression of OX40 at the transcript level and serum protein levels were measured by quantitative real-time
polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assays respectively.
Results:
The mean expression level of OX40 was increased in patients but not at a significant level (P>0.05).
Consistently, the mean serum concentration of OX40 showed a mild, but non-significant, increase in the patients
(P>0.05).
Conclusion:
We conclude that OX40 expression at either the transcript or protein level has no diagnostic utility in
asymptomatic PD. This shows the need for clinical, cellular and interventional research to detect new robust biomarkers.
